Dorsomorphin

BMP and AMPK pathway inhibitor; Inhibits ALK2, ALK3, ALK6, and AMPK

Dorsomorphin

BMP and AMPK pathway inhibitor; Inhibits ALK2, ALK3, ALK6, and AMPK

From: 265 USD
Catalog #
72102_C
BMP and AMPK pathway inhibitor; Inhibits ALK2, ALK3, ALK6, and AMPK

Overview

Dorsomorphin inhibits the bone morphogenetic protein (BMP) pathway by targeting the type I BMP receptors activin receptor-like kinase (ALK) 2, ALK3, and ALK6. It is also a potent inhibitor of AMP-activated protein kinase (AMPK; Ki = 109 nM) but does not significantly inhibit structurally related kinases such as ZAPK, SYK, PKCθ, PKA, or JAK3 (Bain et al., Yu et al.). 

DIFFERENTIATION
· Promotes differentiation of neural progenitor cells from human pluripotent stem cells (Morizane et al., Zhou et al.).
· Promotes differentiation of cardiomyocytes from mouse and human pluripotent stem cells (Hao et al., Kattman et al.).
· Promotes differentiation of adipocytes and suppresses osteogenic differentiation of osteoblasts from human mesenchymal cells (Kim et al.).
Alternative Names
Compound C
Cell Type
Adipocytes, Cardiomyocytes, PSC-Derived, Mesenchymal Stem and Progenitor Cells, Neural Cells, PSC-Derived, Pluripotent Stem Cells
Species
Human, Mouse, Rat, Non-Human Primate, Other
Application
Differentiation
Area of Interest
Neuroscience, Stem Cell Biology
CAS Number
866405-64-3
Chemical Formula
C₂₄H₂₅N₅O
Molecular Weight
399.5 g/mol
Purity
≥ 98%
Pathway
AMPK, BMP
Target
ALK2, ALK3, ALK6, AMPK

Scientific Resources

Product Documentation

Find supporting information and directions for use in the Product Information Sheet or explore additional protocols below.

Document Type
Product Name
Catalog #
Lot #
Language
Product Name
Dorsomorphin
Catalog #
72102, 100-0246
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
Dorsomorphin
Catalog #
72102
Lot #
All
Language
English
Document Type
Safety Data Sheet
Product Name
Dorsomorphin
Catalog #
100-0246
Lot #
All
Language
English

Product Applications

Data and Publications

Publications (7)

Human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by AMP-activated protein kinase. Kim E-K et al. Journal of cellular physiology 2012 APR

Abstract

AMP-activated protein kinase (AMPK) is an energy-sensing kinase that has recently been shown to regulate the differentiation of preadipocytes and osteoblasts. However, the role of AMPK in stem cell differentiation is largely unknown. Using in vitro culture models, the present study demonstrates that AMPK is a critical regulatory factor for osteogenic differentiation. We observed that expression and phosphorylation of AMPK were increased during osteogenesis in human adipose tissue-derived mesenchymal stem cells (hAMSC). To elucidate the role of AMPK in osteogenic differentiation, we investigated the effect of AMPK inhibition or knockdown on mineralization of hAMSC. Compound C, an AMPK inhibitor, reduced mineralized matrix deposition and suppressed the expression of osteoblast-specific genes, including alkaline phosphatase (ALP), runt-related transcription factor 2 (RUNX2), and osteocalcin (OCN). Knockdown of AMPK by shRNA-lentivirus infection also reduced osteogenesis. In addition, inhibition or knockdown of AMPK during osteogenesis inhibited ERK phosphorylation, which is required for osteogenesis. Interestingly, inhibition of AMPK induced adipogenic differentiation of hAMSC, even in osteogenic induction medium (OIM). These results provide a potential mechanism involving AMPK activation in osteogenic differentiation of hAMSC and suggest that commitment of hAMSC to osteogenic or adipogenic lineage is governed by activation or inhibition of AMPK, respectively.
Small-molecule inhibitors of bone morphogenic protein and activin/nodal signals promote highly efficient neural induction from human pluripotent stem cells. Morizane A et al. Journal of neuroscience research 2011 FEB

Abstract

The balance of bone morphogenic protein (BMP), transforming growth factor-β (TGFβ)/activin/nodal, and Wnt signals regulates the early lineage segregation of human embryonic stem cells (ESCs). Here we demonstrate that a combination of small-molecule inhibitors of BMP (Dorsomorphin) and TGFβ/activin/nodal (SB431542) signals promotes highly efficient neural induction from both human ESCs and induced pluripotent stem cells (iPSCs). The combination of small molecules had effects on both cell survival and purity of neural differentiation, under conditions of stromal (PA6) cell coculture and feeder-free floating aggregation culture, for all seven pluripotent stem cell lines that we studied, including three ESC and four iPSC lines. Small molecule compounds are stable and cost effective, so our findings provide a promising strategy for controlled production of neurons in regenerative medicine.
Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Kattman SJ et al. Cell stem cell 2011 FEB

Abstract

Efficient differentiation of embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) to a variety of lineages requires step-wise approaches replicating the key commitment stages found during embryonic development. Here we show that expression of PdgfR-α segregates mouse ESC-derived Flk-1 mesoderm into Flk-1(+)PdgfR-α(+) cardiac and Flk-1(+)PdgfR-α(-) hematopoietic subpopulations. By monitoring Flk-1 and PdgfR-α expression, we found that specification of cardiac mesoderm and cardiomyocytes is determined by remarkably small changes in levels of Activin/Nodal and BMP signaling. Translation to human ESCs and iPSCs revealed that the emergence of cardiac mesoderm could also be monitored by coexpression of KDR and PDGFR-α and that this process was similarly dependent on optimal levels of Activin/Nodal and BMP signaling. Importantly, we found that individual mouse and human pluripotent stem cell lines require optimization of these signaling pathways for efficient cardiac differentiation, illustrating a principle that may well apply in other contexts.

Contact STEMCELL Technologies

Our Customer Service, Sales, and Product and Scientific Support departments in North America are available between 6 am and 5 pm Pacific Time (9 am and 8 pm Eastern Time). One of our representatives will be happy to help you by telephone or email. Please complete the form to contact us by email. A representative will get back to you shortly.
  •  

StemCell Technologies Inc. and affiliates ("STEMCELL Technologies") does not share your email address with third parties. StemCell Technologies Inc. will use your email address to confirm your identity and send you newsletters, transaction-related emails, promotional and customer service emails in accordance with our privacy policy. You can change your email preferences at any time.